Product Code: SSCN03_20180101
BMI View: China's evolving demographic and epidemiological profiles will act as key drivers of growth within the country's pharmaceuticals and healthcare markets over the coming years. While rising chronic diseases and developments in the healthcare system will support market expansion, tough pricing regime and a large counterfeit industry pose downside risks for multinational drugmakers. Nevertheless, the size of the market and the overall trend towards regulatory improvement will continue to prove major draws.
Table of Contents
BMI Industry View
- Table: Headline Pharmaceuticals & Healthcare Forecasts (China 2015-2021)
SWOT
Industry Forecast
- Pharmaceutical Market Forecast
- Table: Pharmaceutical Sales, Historical Data And Forecasts (China 2013-2021)
- Healthcare Market Forecast
- Table: Healthcare Expenditure Trends, Historical Data And Forecasts (China 2013-2021)
- Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (China 2013-2021)
- Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (China 2013-2021)
- Prescription Drug Market Forecast
- Table: Prescription Drug Market Indicators, Historical Data And Forecasts (China 2013-2021)
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators, Historical Data And Forecasts (China 2013-2021)
- Generic Drug Market Forecast
- Table: Generic Drug Market Indicators, Historical Data And Forecasts (China 2013-2021)
- OTC Market Forecast
- Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (China 2013-2021)
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Trade Data And Forecasts (China 2015-2021)
- Table: Pharmaceutical Trade Data And Forecasts local currency (China 2015-2021)
Industry Risk/Reward Index
- Asia Pacific Pharmaceuticals: Diverse Opportunities And Inherent Risks
- China Risk/Reward Index
Regulatory Review
- Intellectual Property Issues
- Table: PHRMA's Special 301 submission, China, 2014-17
- Pricing Regime
- China - 13th Five-Year Plan To Reinforce Existing Trends
Market Overview
- Healthcare Sector
- Table: Healthcare Resources (China 2011-2016)
- Table: Healthcare Personnel (China 2011-2016)
- Table: Healthcare Activity (China 2011-2016)
- Research & Development
- Clinical Trials
- Epidemiology
- Table: Estimated Number Of New Cases Of Cancer In China
Competitive Landscape
- Research-Based Industry
- Table: Multinational Market Activity
- Generic Drugmakers
- Pharmaceutical Distribution
Company Profile
- AstraZeneca
- Bayer
- China Shijiazhuang Pharmaceutical Group
- Eli Lilly
- GlaxoSmithKline
- Merck & Co
- Merck KGaA
- North China Pharmaceutical Corporation
- Novartis
- Pfizer
- Roche
- Sanofi
- Shanghai Pharmaceutical
- Sinopharm
Appendix
- 13th Five-Year Plan: Key Points
- Summary Of Contents
- Chapter 1: Overview
- Chapter 2: Innovation To Drive Development
- Chapter 3: Economic Institutions
- Chapter 4: Modernisation Of The Agricultural Sector
- Chapter 5: Industries
- Chapter 6: Expand The Network Economy
- Chapter 7: Build A Modern Infrastructure Network
- Chapter 8: New-Type Urbanisation
- Chapter 9: Coordination Of Regional Development
- Chapter 10: Environmental Protection
- Chapter 11: Continue Opening Up
- Others:
Demographic Forecast
- Table: Population Headline Indicators (China 1990-2025)
- Table: Key Population Ratios (China 1990-2025)
- Table: Urban/Rural Population & Life Expectancy (China 1990-2025)
- Table: Population By Age Group (China 1990-2025)
- Table: Population By Age Group % (China 1990-2025)
Glossary
Methodology
- Pharmaceutical Expenditure Forecast Model
- Healthcare Expenditure Forecast Model
- Notes On Methodology
- Risk/Reward Index Methodology
- Table: Indicators - Rationale And Sources
